Brief: Herantis: Inconclusive Results From Phase II Study With Lymfactin In BCRL

Herantis Pharma Oyj

02/03/2021 12:04

March 2 (Reuters) - Herantis Pharma Oyj  HRTIS.HE :
    * HERANTIS ANNOUNCES INCONCLUSIVE RESULTS FROM PHASE II STUDY WITH LYMFACTIN IN BREAST
CANCER
RELATED LYMPHEDEMA 
    * CLINICAL TRIAL RESULTS FROM ITS PHASE II STUDY INVESTIGATING HERANTIS'PATENTED GENE
THERAPY
LYMFACTIN®,FOR TREATMENT OF BREAST CANCER RELATED LYMPHEDEMA (BCRL), WERE INCONCLUSIVE
    * FROM A SAFETY PERSPECTIVE, LYMFACTIN WAS GENERALLY SAFE AND WELL TOLERATED
    *  COMPANY EXPECTS TO BE ABLE TO ANNOUNCE ANY FURTHER FINDINGS AND DECISIONS ON PROGRAM IN
Q2
2021.
    * RESULTS UNEXPECTEDLY SHOWED DIFFERENCES BETWEEN TREATMENT GROUPS AT STARTOF STUDY
(BASELINE), IN
TERMS OF ARM VOLUME AND QUALITY OF LIFE, MAKING IT UNFEASIBLE TO DRAW CONCLUSIONS ON TREATMENT
EFFECTOF LYMFACTIN® IN COMBINATION WITH SURGERY, COMPARED TO SURGERY ALONE.
    * PURPOSE OF TRIAL WAS TO DETERMINE WHETHER THERE WAS ADDITIONAL BENEFIT OF LYMFACTIN
TREATMENT IN
COMBINATION WITH LYMPH NODE TRANSFER SURGERY, COMPARED TO SURGERY ALONE
    * WHILE BOTH TREATMENT GROUPS EXPERIENCED CLEAR CLINICAL BENEFITS, TRIAL DID NOT ESTABLISH
ADDITIONAL TREATMENT BENEFIT FOR LYMFACTIN IN COMBINATION WITH SURGERY, COMPARED TO SURGERY
ALONE

Source text for Eikon:  ID:nWkr1y8hTz 
Further company coverage:  HRTIS.HE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))